RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF

Renalytix plc

Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024

$3.56+0.06 (+1.57%)

Close on Oct 19, 2026

Market cap: $375.75M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Sep 30, 2024

Renalytix reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Renalytix's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Renalytix's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Dec 16, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RNLXY.

Revenue growth-18.7% · median 27.6%

Gross margin12.7% · median -45.7%

Operating margin-1054.9% · median -19.3%

Net margin-1191.8% · median -26.8%

Company	Revenue	Growth
CDNA	$458.09M	+34.4%
BDSX	$102.94M	+34.5%
XGN	$71.12M	+20.8%
RNLXY	$2.35M	-18.7%
SERA	$70.00K	-35.2%
MDXH	–	–

Company

Exchange: OTC
Industry: Services-Medical Laboratories
Fiscal year ends: June 30
Auditor: CohnReznick
SEC CIK: 1811115

Advertisement
300 × 250